{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:06:40Z","timestamp":1788577600953,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1053\/j.ajkd.2025.09.030","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:13:16Z","timestamp":1774051996000},"page":"835-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review"],"prefix":"10.1053","volume":"87","author":[{"given":"David J.","family":"Leehey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1053\/j.ajkd.2025.09.030_bib1","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.09.030_bib2","first-page":"S124","article-title":"11. Microvascular complications and foot care: standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1053\/j.ajkd.2025.09.030_bib3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.09.030_bib4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2025.09.030_bib6","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.030_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.030_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ki.1991.308","article-title":"Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy","volume":"40","author":"Hasegawa","year":"1991","journal-title":"Kidney Int"},{"issue":"14","key":"10.1053\/j.ajkd.2025.09.030_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143393","article-title":"Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease","volume":"20","author":"Matoba","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.ajkd.2025.09.030_bib12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1797.2006.00576.x","article-title":"Macrophage accumulation in human progressive diabetic nephropathy","volume":"11","author":"Nguyen","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"10.1053\/j.ajkd.2025.09.030_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.imlet.2017.04.003","article-title":"Serum TNF- concentrations in type 2 diabetes mellitus patients and diabetic nephropathy patients: a systematic review and meta-analysis","volume":"186","author":"Chen","year":"2017","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.030_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CN110223","article-title":"Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy","volume":"97","author":"Sanchez-Alamo","year":"2022","journal-title":"Clin Nephrol"},{"issue":"26","key":"10.1053\/j.ajkd.2025.09.030_bib15","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"De Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2025.09.030_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1681\/ASN.0000000000000444","article-title":"Selonsertib in patients with diabetic kidney disease: a phase 2b randomized active run-in clinical trial","volume":"35","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.030_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11906-015-0612-7","article-title":"Pentoxifylline for diabetic nephropathy: an important opportunity to re-purpose an old drug?","volume":"18","author":"Bhanot","year":"2016","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.030_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/j.1875-9114.1984.tb03380.x","article-title":"Pentoxifylline: a new drug for the treatment of intermittent claudication: mechanism of action, pharmacokinetics, clinical efficacy and adverse effects","volume":"4","author":"Aviado","year":"1984","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1053\/j.ajkd.2025.09.030_bib19","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/ckj\/sfac143","article-title":"Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease","volume":"15","author":"Donate-Correa","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.030_bib20","doi-asserted-by":"crossref","first-page":"c73","DOI":"10.1159\/000083417","article-title":"Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus","volume":"99","author":"Aminorroaya","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.030_bib21","first-page":"790","article-title":"The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial","volume":"32","author":"Ghorbani","year":"2012","journal-title":"Nefrologia"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib22","first-page":"116","article-title":"Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients","volume":"43","author":"Guerrero-Romero","year":"1995","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2025.09.030_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13098-015-0060-1","article-title":"Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study","volume":"7","author":"Han","year":"2015","journal-title":"Diabetol Metab Syndr"},{"key":"10.1053\/j.ajkd.2025.09.030_bib24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1081\/JDI-120021159","article-title":"Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients","volume":"25","author":"Harmankaya","year":"2003","journal-title":"Ren Fail"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.030_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonzalez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.09.030_bib26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2337\/diacare.22.6.1006","article-title":"Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy","volume":"22","author":"Navarro","year":"1999","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0272-6386(03)00651-6","article-title":"Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study","volume":"42","author":"Navarro","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2025.09.030_bib28","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1681\/ASN.2005010001","article-title":"Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial","volume":"16","author":"Navarro","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.030_bib29","first-page":"309","article-title":"Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients","volume":"2","author":"Oliaei","year":"2011","journal-title":"Caspian J Intern Med"},{"key":"10.1053\/j.ajkd.2025.09.030_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5414\/CNP64091","article-title":"Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients: a randomized, equivalent trial","volume":"64","author":"Rodr\u00edguez-Mor\u00e1n","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2025.09.030_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5414\/CNP66003","article-title":"Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial","volume":"66","author":"Rodr\u00edguez-Mor\u00e1n","year":"2006","journal-title":"Clin Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/08860221003602645","article-title":"Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy","volume":"32","author":"Roozbeh","year":"2010","journal-title":"Ren Fail"},{"key":"10.1053\/j.ajkd.2025.09.030_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/259592","article-title":"Effect of pentoxifylline on microalbuminuria in diabetic patients: a randomized controlled trial","author":"Shahidi","year":"2015","journal-title":"Int J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.030_bib34","first-page":"15","article-title":"Determination of pentoxifylline efficacy on microalbuminuria in patients with type-2 diabetes","volume":"115","author":"Shayanpour","year":"2024","journal-title":"Recenti Prog Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.030_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02732042","article-title":"Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy","volume":"24","author":"Solerte","year":"1987","journal-title":"Acta Diabetol Lat"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.030_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.030_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053019","article-title":"Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial","volume":"11","author":"Leehey","year":"2021","journal-title":"BMJ Open"},{"key":"10.1053\/j.ajkd.2025.09.030_bib38","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2008.01.025","article-title":"The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis","volume":"52","author":"McCormick","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.030_bib39","article-title":"Pentoxifylline for diabetic kidney disease","volume":"2012","author":"Shan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1053\/j.ajkd.2025.09.030_bib40","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1007\/s00210-023-02842-6","article-title":"The effect of a methylxanthine vasodilator: pentoxifylline on the treatment of diabetic nephropathy\u2014a meta-analysis","volume":"397","author":"Zhang","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:25:03Z","timestamp":1781825103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626007535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0272638626007535"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.030","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is There a Role for Pentoxifylline in Diabetic Kidney Disease? A Mini Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}